Task 03/13: Product Development Plans for Vaccines

NIH RePORTER · NIH · N01 · $95,183 · view on reporter.nih.gov ↗

Abstract

The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models. This contract also provides testing of vaccines for safety and immunogenicity, to include humoral and cellular immunity, in small animals as well as non-human primates, under GLP where appropriate. In addition, it can perform testing of therapeutics for safety and pharmacology, in small animals as well as non-human primates, under GLP where appropriate.

Key facts

NIH application ID
10162359
Project number
N01AI40005-P00015-9999-2
Recipient
SRI INTERNATIONAL
Principal Investigator
LAURENCE LEMIALE
Activity code
N01
Funding institute
NIH
Fiscal year
2020
Award amount
$95,183
Award type
Project period
2003-11-20 → 2012-06-30